14-day Premium Trial Subscription Try For FreeTry Free

Latest Data & Signals Issued

Signal Type Signal Value Data
Score 0.000 63 days ( -0.633 % )
Last Price $0.151 0 %
High/ Low $0.151 - $0.151 0%
Chg 7 Days N/A $0.151 $0.151
Chg 30 Days N/A $0.151 $0.151
Chg 12 mos -93.23 % $2.23 $0.151
Trend - 3 mos N/A Width: 0.00000000 %
Trend - 12 mos -58.21 % Width: 226.30 %
Pred. range - 3 mos $0.151 - $0.151 0 % - 0 %
Pred. range - 12 mos N/A - $0.563 -100.00 % - 272.91 %
Short MA avg 3 mos Sell 0000-00-00 - N/A days
Long MA avg 3 mos Sell 0000-00-00 - N/A days
Short/Long MA avg 3 mos Sell 0000-00-00 - N/A days
Short MA avg 12 mos Buy 2023-01-10 - 69 days
Long MA avg 12 mos Sell 2022-09-13 - 151 days
Short/Long MA avg 12 mos Sell 2022-08-08 - 176 days
Pivot Short Sell 2023-04-18 - 2 days
Bollinger Sell 0000-00-00 - N/A days
MACD N/A No Dates Stored For This Signal
Click to get the best stock tips daily for free!

About Clovis Oncology

Clovis Oncology Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. In Europe, the... CLVS Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT